ARDX
ArdelyxCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The long thesis is primarily a commercial-execution story: IBSRELA grew 73% to $274.2M in 2025, management guides another step-up to $410-430M in 2026, and the company added a formulation patent running to November 26, 2042 for IBSRELA/XPHOZAH commercial formulations [#8-K-2026-02-19] [#10-K-2026-02-19].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.9.
What can break
2026 operating-expense growth could absorb commercial upside and delay durable cash-flow inflection.
Momentum
7
Value
41
Sentiment
94
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $11.50 · Bear $4.20
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $16.30
Why
Momentum7 · Δ7d -2.1
Value41 · Δ7d +0.0
Sentiment94 · Δ7d -3.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
7
26% active weight
Current posture
7d trendFlat
Δ7d
-2.1
Δ21d
-20.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
94
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.9
Δ21d
+7.1
Why this grade
Composite grade C. Momentum 6.9 / Value 41.1 / Sentiment 94.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.26B
Beta
0.56
Shares Out
247.03M
P/E (TTM) · Derived
-19.9
P/S (TTM)
3.72
P/FCF (TTM) · Derived
-32.97
Rev YoY
+27.5%
EPS YoY
-11.3%
Gross Margin
+91.7%
Op Margin
-9.5%
Net Debt
-$56.74M
Current Ratio
3.49
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology